18 February 2022
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, announces that, ahead of the general meeting of the Company to be held on 7 March 2022, Dr Simon Douglas (Chairman), Jag Grewal (CEO) and Chris Lea (CFO) will provide a live presentation relating to the Company’s recently announced conditional sale of its Alva facility and new strategic focus, and also on the possible consequences for the Group should the resolutions to be proposed at the general meeting in respect of the proposed placing and open offer by the Company not be passed.
The presentation will be provided via the Investor Meet Company platform on Thursday 24 February 2022 at 4:30pm GMT.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet OMEGA DIAGNOSTICS GROUP PLC via:
Investors who already follow OMEGA DIAGNOSTICS GROUP PLC on the Investor Meet Company platform will automatically be invited.
|Omega Diagnostics Group PLC||www.omegadx.com|
|Jag Grewal Chief Executive Officer||via Walbrook PR|
|Chris Lea, Chief Financial Officer|
|finnCap Ltd||Tel: 020 7220 0500|
|Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)|
|Alice Lane/ Charlotte Sutcliffe (ECM)|
|Walbrook PR Limited||Tel: 020 7933 8780 or [email protected]|
|Paul McManus||Mob: 07980 541 893|
|Lianne Applegarth||Mob: 07584 391 303|
|Sam Allen||Mob: 07502 558 258|
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.